Design of nanoformulation of specialized pro-resolving mediators to facilitate inflammation resolution and disease treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Macrophage Migration Inhibitory Factor · Curcumin's Biomedical Applications · Fatty Acid Research and Health
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Signaling organelles of the innate immune system10.1016/j.cell.2012.11.011 ↗
2. Distinct transcription factor networks control neutrophil-driven inflammation10.1038/s41590-021-00968-4 ↗
3. Acute inflammation. A review
4. Inflammation 2010: new adventures of an old flame10.1016/j.cell.2010.03.006 ↗
5. Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases10.1080/14728222.2019.1691525 ↗
6. Engineered nanoerythrocytes alleviate central nervous system inflammation by regulating the polarization of inflammatory microglia10.1002/adma.202201322 ↗
7. Nonresolving inflammation10.1016/j.cell.2010.02.029 ↗
8. Understanding nanomaterial–liver interactions to facilitate the development of safer nanoapplications
9. Engineering CXCL12 biomimetic decoy-integrated versatile immunosuppressive nanoparticle for ischemic stroke therapy with management of overactivated brain immune microenvironment
10. Pattern recognition receptors and inflammation10.1016/j.cell.2010.01.022 ↗
11. Inflammation, ageing and chronic disease10.1016/j.coi.2014.03.007 ↗
12. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging10.1016/j.stem.2022.06.012 ↗
13. The resolution of inflammation: principles and challenges10.1016/j.smim.2015.03.014 ↗
14. Inflammation and tumor progression: signaling pathways and targeted intervention10.1038/s41392-021-00658-5 ↗
15. Specialized pro-resolving mediator network: an update on production and actions10.1042/EBC20200018 ↗
16. The resolution of inflammation: the devil in the flask and in the details10.1096/fj.11-0502ufm ↗
17. Resolution of inflammation: an organizing principle in biology and medicine10.1016/j.pharmthera.2021.107879 ↗
18. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors10.1016/j.mam.2017.03.005 ↗
19. Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-1910.3389/fimmu.2021.632238 ↗
20. When to use biological agents in inflammatory bowel disease10.1111/j.1440-1746.2011.07056.x ↗
21. Pro-resolving lipid mediators are leads for resolution physiology10.1038/nature13479 ↗
22. Voluntary-opsonization-enabled precision nanomedicines for inflammation treatment
23. Encapsulation efficiency of food flavours and oils during spray drying10.1080/07373930802135972 ↗
24. Nano-encapsulation of furosemide microcrystals for controlled drug release10.1016/S0168-3659(02)00322-X ↗
25. Advances in micro and nano-encapsulation of bioactive compounds using biopolymer and lipid-based transporters10.1016/j.tifs.2018.05.018 ↗
26. Nano-encapsulation of fish oil in nano-liposomes and its application in fortification of yogurt10.1016/j.foodchem.2016.08.022 ↗
27. Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice10.1038/s42003-020-01410-5 ↗
28. Remote loading of small-molecule therapeutics into cholesterol-enriched cell-membrane-derived vesicles10.1002/anie.201707598 ↗
29. Cell membrane-derived nanomaterials for biomedical applications10.1016/j.biomaterials.2017.02.041 ↗
30. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy10.1016/j.biomaterials.2017.05.003 ↗
31. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes10.1073/pnas.81.17.5335 ↗
32. Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis10.1016/0006-291X(82)90622-2 ↗
33. Role of polyunsaturated fatty acids in ischemic stroke–a perspective of specialized pro-resolving mediators10.1016/j.clnu.2020.12.037 ↗
34. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution10.1016/j.plefa.2005.05.002 ↗
35. Anti-inflammatory and pro-resolving properties of benzo-lipoxin A4 analogs10.1016/j.plefa.2009.09.004 ↗
36. Resolvin E1 and protectin D1 activate inflammation-resolution programmes10.1038/nature05877 ↗
37. Role of resolvins in the inflammatory resolution of neurological diseases10.3389/fphar.2020.00612 ↗
38. Lipid mediator class switching during acute inflammation: signals in resolution10.1038/89759 ↗
39. Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation
40. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators10.1172/JCI97943 ↗
41. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2–nonsteroidal antiinflammatory drugs and transcellular processing10.1084/jem.192.8.1197 ↗
42. Cyclooxygenase-2-derived prostaglandin and lipoxin accelerate resolution of allergic edema in angiostrongylus costaricensis infected rats: relationship with concurrent eosinophilia10.4049/jimmunol.164.2.1029 ↗
43. Cutting edge: human vagus produces specialized proresolving mediators of inflammation with electrical stimulation reducing proinflammatory eicosanoids10.4049/jimmunol.1800806 ↗
44. Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans10.1093/ajcn/nqz016 ↗
45. Resolvin E3 attenuates allergic airway inflammation Via the interleukin-23-interleukin-17A pathway10.1096/fj.201900283R ↗
46. Association of the resolvin precursor 17-HDHA, but Not D- or E- series resolvins, with heat pain sensitivity and osteoarthritis pain in humans10.1038/s41598-017-09516-3 ↗
47. Specialized proresolving mediators in infection and lung injury10.1002/biof.1691 ↗
48. Pulmonary delivery of specialized pro-resolving mediators-based nanotherapeutics attenuates pulmonary fibrosis in preclinical animal models10.1021/acsnano.2c10388 ↗
49. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease10.1038/s41467-019-11928-w ↗
50. Aspirin-triggered proresolving mediators stimulate resolution in cancer10.1073/pnas.1804000116 ↗
51. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses10.1126/scitranslmed.aaf7483 ↗
52. Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes10.1096/fj.201801017R ↗
53. Myeloid ALX/FPR2 regulates vascularization following tissue injury10.1073/pnas.1918163117 ↗
54. Resolvin D1 halts remote neuroinflammation and improves functional recovery after focal brain damage via ALX/FPR2 receptor-regulated microRNAs10.1007/s12035-018-0889-z ↗
55. Identification of resolvin D2 receptor mediating resolution of infections and organ protection10.1084/jem.20150225 ↗
56. Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease10.3389/fphar.2018.01273 ↗
57. Aspirin triggered resolvin D1 reduces inflammation and restores saliva secretion in a sjögren’s syndrome mouse model10.1093/rheumatology/kez072 ↗
58. Peripheral interaction of resolvin D1 and E1 with opioid receptor antagonists for antinociception in inflammatory pain in rats10.3389/fnmol.2017.00242 ↗
59. Resolvin E1 ameliorates pulpitis by suppressing dental pulp fibroblast activation in a chemerin receptor 23-dependent manner10.1016/j.joen.2019.05.005 ↗
60. Expression and cell distribution of leukotriene B4 receptor 1 in the rat brain cortex after experimental subarachnoid hemorrhage10.1016/j.brainres.2016.10.006 ↗
61. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR2310.1007/s00213-017-4774-7 ↗
62. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions10.1172/JCI129448 ↗
63. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation10.1016/j.immuni.2014.02.009 ↗
64. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis10.1016/j.bcp.2013.07.002 ↗
65. RvE1 uses the LTB4 receptor BLT1 to increase [Ca2+]i and stimulate mucin secretion in cultured rat and human conjunctival goblet cells10.1016/j.jtos.2020.04.011 ↗
66. Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway10.1371/journal.pone.0174936 ↗
67. Biosynthesis of D-series resolvins in skin provides insights into their role in tissue repair10.1016/j.jid.2018.03.1498 ↗
68. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells10.4049/jimmunol.156.6.2264 ↗
69. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils10.1021/bi00044a041 ↗
70. LXA4, aspirin-triggered 15-Epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation10.1152/ajpcell.1999.276.4.C988 ↗
71. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers10.1172/JCI116601 ↗
72. Lipoxin A4 regulates bronchial epithelial cell responses to acid injury10.2353/ajpath.2006.051056 ↗
73. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction10.1084/jem.183.1.137 ↗
74. Lipoxin A and aspirin-triggered 15-epi-lipoxin A inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes10.1073/pnas.202296999 ↗
75. Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: studies on stereospecificity of inhibition and mode of action10.4049/jimmunol.138.1.266 ↗
76. Lipoxin A regulates natural killer cell and type 2 innate lymphoid cell activation in asthma10.1126/scitranslmed.3004812 ↗
77. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity10.1038/ni745 ↗
78. Aspirin-triggered lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly10.1038/sj.onc.1209002 ↗
79. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine10.1111/j.1398-9995.1994.tb02654.x ↗
80. Lipoxin A inhibits IL-1β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases10.4049/jimmunol.164.5.2660 ↗
81. Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor10.1165/rcmb.2005-0184OC ↗
82. Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines10.1165/rcmb.2006-0172OC ↗
83. Specialized pro-resolving mediators: it’s anti-oxidant stress role in multiple disease models10.1016/j.molimm.2020.07.017 ↗
84. The lipid mediator resolvin D1 reduces the skin inflammation and oxidative stress induced by UV irradiation in hairless mice10.3389/fphar.2018.01242 ↗
85. Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress10.1111/j.1476-5381.2009.00234.x ↗
86. Aspirin-triggered resolvin D1 alleviates paraquat-induced acute lung injury in mice10.1016/j.lfs.2018.12.028 ↗
87. Maresin 1 mitigates renal ischemia/reperfusion injury in mice via inhibition of the TLR4/MAPK/NF-ΚB pathways and activation of the Nrf2 pathway10.2147/DDDT.S188654 ↗
88. Proresolving lipid mediators: endogenous modulators of oxidative stress
89. Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in Vivo: implications for the prevention of fetal alcohol spectrum disorders10.1089/ars.2007.2019 ↗
90. PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells10.1016/j.cardiores.2005.01.026 ↗
91. Resolvin D1 mitigates energy metabolism disorder after ischemia–reperfusion of the rat lung10.1186/s12967-016-0835-7 ↗
92. Cyclic nucleotide research-still expanding after half a century10.1038/nrm911 ↗
93. Blame the signaling: role of cAMP for the resolution of inflammation10.1016/j.phrs.2020.105030 ↗
94. Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis10.1165/rcmb.2012-0424OC ↗
95. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections10.1172/JCI131609 ↗
96. A cluster of immunoresolvents links coagulation to innate host defense in human blood10.1126/scisignal.aan1471 ↗
97. Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na,K-ATPase Via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury10.4049/jimmunol.1302421 ↗
98. Resolvin E1 selectively interacts with leukotriene b receptor BLT1 and ChemR23 to regulate inflammation10.4049/jimmunol.178.6.3912 ↗
99. Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding10.4049/jimmunol.135.5.3434 ↗
100. Lipoxin A4 activates alveolar epithelial sodium channel, Na, K-ATPase, and increases alveolar fluid clearance10.1165/rcmb.2012-0274OC ↗